Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-134-VI | Volasertib | PLK | Cell cycle | 0.0027209 | -0.6274 | 1.0260 | 0.2671 | 5.0000 | 0.0032225 | 0.99553 |
HCC1500 | ABT-737 | Bcl2/XL | Misc | 0.0085142 | -0.7359 | 1.1288 | 0.3716 | 0.9283 | 0.022222 | 0.99554 |
HCC1395 | Ceritinib | ALK | RTK | 1.6025 | -0.6268 | 0.2363 | 0.0809 | 1.8434 | 2.6534 | 0.99554 |
BT-549 | Ceritinib | ALK | RTK | 2.961 | -0.2284 | 0.1416 | 0.0526 | 1.8781 | 4.216 | 0.99556 |
PDX1258 | Tivantinib | MET | RTK | 0.39607 | -0.2089 | 0.3834 | 0.1084 | 1.2903 | 0.54289 | 0.9956 |
HCC1806 | Vorinostat | HDAC | Misc | 1.1276 | 0.0178 | 0.2397 | 0.0491 | 1.3263 | 1.2167 | 0.99564 |
MCF7 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.069398 | 0.1574 | 0.4829 | 0.0400 | 1.6265 | 0.055227 | 0.99565 |
T47D | Tivantinib | MET | RTK | 0.3478 | -0.1544 | 0.3824 | 0.1267 | 3.7033 | 0.37139 | 0.99567 |
Hs 578T | Vorinostat | HDAC | Misc | 0.90288 | -0.1689 | 0.2728 | 0.1049 | 2.2431 | 1.0225 | 0.99568 |
CAL-85-1 | Cediranib | VEGFR/cKIT | RTK | 2.4003 | -0.2379 | 0.1869 | 0.0514 | 1.1002 | 6.5151 | 0.99569 |
HCC70 | Abemaciclib | CDK4/6 | Cell cycle | 1.885 | -0.8264 | 0.2315 | 0.0832 | 2.5102 | 2.8439 | 0.99569 |
SK-BR-3 | Tivantinib | MET | RTK | 0.27263 | -0.3523 | 0.4830 | 0.2060 | 2.4177 | 0.34098 | 0.99571 |
SK-BR-3 | Doxorubicin | Chemo | Chemotherapy | 0.0067336 | -0.6156 | 0.9421 | 0.3142 | 1.5278 | 0.010801 | 0.99572 |
HCC38 | Ceritinib | ALK | RTK | 1.8283 | -0.4039 | 0.2184 | 0.0883 | 2.6153 | 2.323 | 0.99573 |
HCC1428 | Tivantinib | MET | RTK | 0.2516 | 0.0341 | 0.3664 | 0.1106 | 2.2041 | 0.23715 | 0.99573 |
MDA-MB-468 | Ceritinib | ALK | RTK | 0.76749 | -0.7415 | 0.4050 | 0.1730 | 1.6622 | 1.3833 | 0.99574 |
SUM149PT | Taxol | Chemo | Chemotherapy | 0.0015927 | -0.2583 | 0.8405 | 0.3816 | 3.1045 | 0.0017914 | 0.99574 |
BT-20 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.012881 | -0.0045 | 0.5675 | 0.1137 | 1.3697 | 0.01193 | 0.99574 |
MDA-MB-468 | Etoposide | Topo II | Chemotherapy | 0.48754 | -0.5132 | 0.4291 | 0.1644 | 1.8475 | 0.69756 | 0.99577 |
MDA-MB-468 | Neratinib | EGFR/HER2 | RTK | 0.15781 | -0.3825 | 0.3861 | 0.1513 | 0.8303 | 0.41607 | 0.99579 |
MDA-MB-231 | Ceritinib | ALK | RTK | 0.86565 | -0.3326 | 0.3444 | 0.1014 | 1.9065 | 1.1609 | 0.99581 |
HCC1937 | Ceritinib | ALK | RTK | 3.5257 | -0.5730 | 0.1368 | 0.0730 | 2.2956 | 5.6897 | 0.99584 |
HCC1428 | Ceritinib | ALK | RTK | 1.2414 | -0.8673 | 0.3014 | 0.1288 | 1.6178 | 2.4481 | 0.99584 |
BT-549 | Volasertib | PLK | Cell cycle | 0.0088352 | -0.2289 | 0.5676 | 0.1490 | 2.4967 | 0.0098732 | 0.99586 |
MDA-MB-231 | ABT-737 | Bcl2/XL | Misc | 3.031 | -0.1204 | 0.1616 | 0.0795 | 1.1097 | 8.1572 | 0.99586 |